AVDL · As filed with the SEC

Avadel Pharmaceuticals balance sheet, by fiscal year

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	51,371	31,167	73,981	50,708
Marketable securities	22,406	73,944	22,518	106,513
Accounts receivable, net	34,097	12,103	—	—
Inventories	20,298	10,380	—	—
Research and development tax credit receivable	—	1,322	2,248	2,443
Prepaid expenses and other current assets	6,036	5,286	2,096	32,826
Total current assets	134,208	134,202	100,843	192,490
Property and equipment, net	453	585	839	285
Operating lease right-of-use assets	1,702	2,591	1,713	2,652
Goodwill	16,836	16,836	16,836	16,836
Research and development tax credit receivable	—	332	1,232	1,225
Other non-current assets	11,037	10,152	11,322	33,777
Total assets	164,236	164,698	132,785	247,265
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	—	—	37,668	—
Current portion of long-term debt	—	0	—	—
Current portion of operating lease liability	582	934	960	900
Accounts payable	7,328	11,433	7,890	7,679
Accrued expenses	40,651	24,227	7,334	7,151
Other current liabilities	273	261	1,941	5,270
Total current liabilities	48,834	36,855	55,793	21,000
Long-term debt	—	—	91,614	142,397
Long-term debt	—	0	—	—
Long-term operating lease liability	1,122	1,690	780	1,707
Royalty financing obligation	35,249	32,760	—	—
Other non-current liabilities	5,183	5,654	5,743	3,917
Total liabilities	90,388	76,959	153,930	169,021
Shareholders’ equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at December 31, 2024 and 5,194 issued and outstanding at December 31, 2023	0	52	5	5
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 96,518 issued and outstanding at December 31, 2024 and 89,825 issued and outstanding at December 31, 2023	965	898	628	586
Additional paid-in capital	891,791	855,452	589,783	549,349
Accumulated deficit	(794,328)	(745,496)	(585,220)	(447,756)
Accumulated other comprehensive loss	(24,580)	(23,167)	(26,341)	(23,940)
Total shareholders’ equity	73,848	87,739	(21,145)	78,244
Total liabilities and shareholders’ equity	164,236	164,698	132,785	247,265

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.